Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPR39 | O43194 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GCG | P01275 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406869 | 0.88 | CNR1 (0.46) | GPR52FYNPTGDRCNR1MAP4K4 | |
| SCHEMBL960125 | 0.85 | PTGDR (0.57) | PTGDRCNR1LMNAGPR39KMT2A | |
| SCHEMBL959317 | 0.84 | GPR52 (0.52) | GPR52FYNCNR1MAP4K4KMT2A | |
| SCHEMBL961208 | 0.80 | CNR1 (0.49) | PTGDRCNR1LMNAGPR39KMT2A | |
| SCHEMBL1513331 | 0.78 | FYN (0.48) | GPR52FYNPTGDRMAP4K4LMNA | |
| SCHEMBL960678 | 0.78 | CNR1 (0.50) | GPR52FYNPTGDRCNR1MAP4K4 | |
| SCHEMBL960460 | 0.77 | FYN (0.50) | GPR52FYNMAP4K4KMT2APOLB | |
| SCHEMBL1513123 | 0.76 | FYN (0.46) | GPR52FYNPTGDRMAP4K4 | |
| SCHEMBL1513274 | 0.75 | FYN (0.49) | GPR52FYNPTGDRMAP4K4TSHR | |
| SCHEMBL1513288 | 0.74 | FYN (0.43) | GPR52FYNPTGDRCNR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | GPR52 23/4885FYN 1882/4885PTGDR 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.